Preprint

Review

Antibodies to SARS-CoV-2 and Their Potential for Therapeutic Passive Immunization

Altmetrics

Downloads

1149

Views

726

Comments

A peer-reviewed article of this preprint also exists.

P.J. Klasse^*,John P. Moore

This version is not peer-reviewed

This preprints belongs to the Collection

Preprints on COVID-19 and SARS-CoV-2

Submitted:

17 April 2020

Posted:

19 April 2020

You are already at the latest version

Alerts

Abstract

We review aspects of the antibody response to SARS-CoV-2, the causative agent of the COVID- 19 pandemic. The topics we cover are relevant to immunotherapy with plasma from recovered patients and with monoclonal antibodies against the viral S-protein. The development of vaccines against SARS-CoV-2, an essential public health tool, will also be informed by an understanding of the antibody response in infected patients. Although virus-neutralizing antibodies are likely to protect, antibodies could potentially trigger immunopathogenic events in SARS-CoV-2-infected patients or enhance infection. An awareness of these possibilities may benefit clinicians and the developers of antibody-based therapies and vaccines.

Keywords:

Subject: Biology and Life Sciences - Virology

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.